These choking rescue protocols include abdominal thrusts (also called the “Heimlich” maneuver) for children and adults but not anti-choking devices.
Similar Posts
FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer
On September 9, 2025, the Food and Drug Administration approved gemcitabine intravesical system (Inlexzo, Janssen Biotech, Inc.) for adults with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumorsClinical Outcome Assessments (COA) Qualification Program Submissions
Clinical Outcome Assessments (COA) Qualification Program SubmissionsDiagnostic Intravascular Catheter Recall: Conavi Removes Novasight Hybrid Catheters
This communication is part of the Communications Pilot to Enhance the Medical Device Recall ProgramCDER Quantitative Medicine Center of Excellence (QM CoE)
The Center for Drug Evaluation and Research Quantitative Medicine Center of Excellence is established to facilitate and coordinate the continuous evolution and consistent application of quantitative medicine for drug development and regulatory decision-making across CDER.CDER Staff Member Shares Her Experience in a Breast Cancer Clinical Trial
She was overwhelmed, but she felt the trial was her best chance for a successful outcome.FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in shortage since 2022 due to increased demand.